Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the California Institute for Regenerative ...

"While most Parkinson's disease treatments focus on symptom management, RNDP-001 aims to replace lost neurons, repair damaged neural circuits and restore motor function for patients with moderate to ...

Parkinson's disease affects millions of people around the world. There are actually 10 million people on a worldwide scale that have the neurodegenerative disorder, according to the Parkinson's ...

Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The ...

Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...

People with autism had a higher risk of developing Parkinson's disease early in life. The risk of Parkinson's before age 50 was four times higher in people with versus without autism. A Parkinson's ...

BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the ...